2024 연구성과 (5 / 286)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Military Non-Terrestrial Networks Architecture and Spectrum Sharing Method for Mitigating Jamming Attacks and Multiple Access Interference | The non-terrestrial networks (NTN) have the potential to enhance military operations in the network-centric operational environment (NCOE) through improved communication coverage and connectivity. However, existing NTN cannot satisfy NCOE requirements. To satisfy the requirements, we propose the military NTN (M-NTN) architecture and a novel spectrum-sharing method for coexistence between Low Earth Orbit (LEO) beams and high altitude platforms (HAP) or unmanned aerial vehicles (UAV) cells. M-NTN employ slow frequency hopping (SFH) for primary users (PU) and fast frequency hopping (FFH) for secondary users (SU). To the best of our knowledge, there is no previous work where two different systems simultaneously performed FFH and SFH. We design the SFH method of the PU so that SU can easily access PU's spectrum. Then, we propose two FFH methods, FFHR and A-FFHR, considering SU mobility and mitigating jamming attacks. Mathematical models analyze pulse collision probabilities, showing M-NTN's effective spectrum-sharing and SU performing FFH, which has less multiple access interference among SUs. A-FFHR is effective owing to high jamming detection probability that we ensure via our proposed jamming detection algorithm. We can determine proper network parameters, such as the slot or frame length, to perform jamming detection algorithms via analysis of numerical results. | Jeon, Hyerim; Baek, Hoki | Kyungpook Natl Univ, Sch Comp Sci & Engn, Daegu 37224, South Korea | Baek, Hoki/T-5233-2019 | 58929387900; 35112685500 | jhr020528@knu.ac.kr;neloyou@knu.ac.kr; | IEEE JOURNAL ON SELECTED AREAS IN COMMUNICATIONS | IEEE J SEL AREA COMM | 0733-8716 | 1558-0008 | 42 | 5 | SCIE | ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS | 2024 | 17.2 | 1.0 | 0.71 | 2025-05-07 | 1 | 2 | Jamming; Low earth orbit satellites; Computer architecture; Autonomous aerial vehicles; Satellite broadcasting; Reliability; Time-frequency analysis; Resource management; non-terrestrial network; frequency hopping; spectrum sharing; tactical network | frequency hopping; non-terrestrial network; Resource management; spectrum sharing; tactical network | Antennas; Computer architecture; Jamming; Military communications; Military vehicles; Multiple access interference; Network architecture; Orbits; Reliability analysis; Resource allocation; Signal detection; Spectrum analysis; Jamming; Low earth orbit satellites; Non-terrestrial network; Resource management; Resource resource management; Satellite broadcasting; Spectrum sharing; Tactical network; Terrestrial networks; Time-frequency Analysis; Frequency hopping | English | 2024 | 2024-05 | 10.1109/jsac.2024.3365897 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | THE IMPORTANCE OF PROVEN TREATMENT AS A VACCINE MODEL FOR COVID-19 | . The COVID-19 global pandemic has posed the biggest medical challenge of the past three years, and efforts to eradicate it have involved cross-border collaborations. Recent studies claim that the development and distribution of vaccines is an effective approach to end this infectious disease. However, this study demonstrates that a vaccine alone may not be enough due to differences in the rates of waning immunity induced by infection and vaccination. We propose that both vaccination and treatment are required to halt COVID-19 disease transmission and end the pandemic. From an epidemiological perspective, we employ the SVEIRS model by introducing vaccination and treatment into the compartmental epidemic The experimental results suggest that the pandemic can be ended by performing both vaccination and treatment. However, the development and distribution of vaccines and treatments take time, and control measures must continue until the disease is completely eradicated. | Kim, B. N.; Abbas, W.; Kim, H. K.; Yoon, G.; Kim, H.; Kim, Y.; Kim, S. | Pusan Natl Univ, Finance Fishery Manufacture Ind Math Ctr Big Data, Busan 46241, South Korea; Kyung Hee Univ, Dept Appl Math, Yongin 17104, Gyeonggi Do, South Korea; Pusan Natl Univ, Inst Math Sci, Busan 46241, South Korea; Pusan Natl Univ, Dept Math, Busan 46241, South Korea; Hannam Univ, Dept Math Educ, Daejeon 34430, South Korea; Natl Inst Math Sci, Daejeon 34047, South Korea; Kyungpook Natl Univ, Dept Math, Daegu 41566, South Korea; Pusan Natl Univ, Inst Future Earth, Busan 46241, South Korea | 24281456900; 57871336100; 56319985300; 7103257925; 59449672600; 7410204041; 34978723300 | sangil.kim@pusan.ac.kr; | APPLIED AND COMPUTATIONAL MATHEMATICS | APPL COMPUT MATH-BAK | 1683-3511 | 1683-6154 | 23 | 4 | SCIE | MATHEMATICS, APPLIED | 2024 | 4.3 | 1.0 | 0 | 2025-05-07 | 0 | 1 | COVID-19; Mathematical Model; Vaccine; Treatment. | EPIDEMIC MODEL; HERD-IMMUNITY; DYNAMICS; SPREAD; REVEAL | COVID-19; Mathematical Model; Treatment; Vaccine | English | 2024 | 2024 | 10.30546/1683-6154.23.4.2024.504 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study | Background Chronic hepatitis B virus (HBV) remains a global concern, with current treatments achieving low rates of HBsAg seroclearance. VIR-2218 (elebsiran), a small interfering RNA agent against HBV transcripts, reduces HBsAg concentrations. We aimed to evaluate the safety and antiviral activity of VIR-2218 with and without pegylated interferon-alpha-2a treatment in participants with chronic HBV. Methods This open-label, phase 2 study was conducted at 23 sites in six countries (New Zealand, Australia, Hong Kong, Thailand, South Korea, and Malaysia). Adults (aged 18-65 years) with chronic HBV infection without cirrhosis and with HBsAg more than 50 IU/mL and HBV DNA less than 90 IU/mL who were on continued nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) therapy for 2 months or longer were eligible. Participants were enrolled into one of six cohorts to receive VIR-2218 200 mg subcutaneously every 4 weeks, with or without 180 mu g subcutaneous pegylated interferon-alfa-2a once per week. Cohort 1 received six doses of VIR-2218 (total 20 weeks); cohort 2 received six doses of VIR-2218 starting at day 1, plus 12 doses of pegylated interferon-alfa-2a starting at week 12 (total 24 weeks); cohort 3 received six doses of VIR-2218 and 24 doses of pegylated interferon-alfa-2a (total 24 weeks); cohort 4 received six doses of VIR-2218 and up to 48 doses of pegylated interferon-alfa-2a (total 48 weeks); cohort 5 received up to 13 doses of VIR-2218 and up to 44 doses of pegylated interferon-alfa-2a (total 48 weeks); and cohort 6 received three doses of VIR-2218 and 12 doses of pegylated interferon-alfa-2a (total 12 weeks). The primary endpoints were the incidence of adverse events and clinical assessments (including results of laboratory tests). Secondary endpoints were the mean maximum reduction ofserum HBsAg at any timepoint; the proportion ofparticipants with serum HBsAg seroclearance at any timepoint and for more than 6 months after the end of treatment; and the proportion of participants with antiHBs seroconversion at any timepoint. For patients who were HBeAg-positive, we also assessed the proportion with HBeAg seroclearance or anti-HBe seroconversion at any timepoint. This study is registered with ClinicalTrials.gov, NCT03672188, and is ongoing. Findings Between July 2, 2020, and Nov 2, 2021, 124 individuals were screened for eligibility, 84 of whom were enrolled (15 in cohort 1, 15 in cohort 2, 18 in cohort 3, 18 in cohort 4, 13 in cohort 5, and five in cohort 6). Participants were predominantly HBeAg-negative, Asian, and male (66 [79%] participants were male and 18 [21%] were female). Most treatment emergent adverse events were grades 1-2. Three (20%) participants in cohort 1, four (27%) in cohort 2, eight (44%) in cohort 3, seven (39%) in cohort 4, six (46%) in cohort 5, and two (40%) in cohort 6 reported treatment- emergent adverse events related to VIR-2218. 12 (80%) participants in cohort 2, 12 (67%) in cohort 3, 14 (78%) in cohort 4, 13 (100%) in cohort 5, and three (60%) in cohort 6 reported treatment-emergent adverse events related to pegylated interferon-alfa-2a. Two (13%) participants in cohort 1 had elevations in alanine aminotransferase, compared with 13 (87%) participants in cohort 2, 15 (83%) in cohort 3, 17 (94%) in cohort 4, 11 (85%) in cohort 5, and three (60%) in cohort 6. The mean maximum change from baseline at any timepoint in HBsAg concentration was -20 log10 IU/mL (95% CI -21 to -18) in cohort 1, -22 log10 IU/mL (-25 to -18) in cohort 2, -25 log10 IU/mL (-28 to -21) in cohort 3, -24 log10 IU/mL (-31 to -18) in cohort 4, -30 log10 IU/mL (-37 to -23) in cohort 5, and -17 log10 IU/mL (-21 to -14) in cohort 6. 11 participants (one in cohort 2, one in cohort 3, five in cohort 4, and four in cohort 5) receiving VIR-2218 plus pegylated interferon-alfa-2a had HBsAg seroclearance at any timepoint. Of these, ten (91%; one in cohort 2, five in cohort 4, and four in cohort 5) had anti-HBs seropositivity. Six participants (one in cohort 2, three in cohort 4, and two in cohort 5) had sustained HBsAg seroclearance through to 24 weeks after the end of treatment. No participants receiving VIR-2218 monotherapy (cohort 1) or VIR-2218 plus pegylated interferon-alfa-2a 12-week regimen (cohort 6) had HBsAg seroclearance. 12 (42%) of 26 participants (one of four in cohort 1, two of six in cohort 2, four of seven in cohort 3, four of six in cohort 4, and one of three in cohort 5) who were HBeAg positive at baseline had HBeAg seroclearance or anti-HBe seroconversion. Interpretation The results of this phase 2 study support further development of VIR-2218 as a potential therapy for patients with chronic HBV infection. Additional clinical trials of VIR-2218 with and without pegylated interferon-alfa-2a in combination with an HBsAg-targeting monoclonal antibody are ongoing. | Yuen, Man-Fung; Lim, Young-Suk; Yoon, Ki Tae; Lim, Tien-Huey; Heo, Jeong; Tangkijvanich, Pisit; Tak, Won Young; Thanawala, Vaidehi; Cloutier, Daniel; Mao, Shenghua; Arizpe, Andre; Cathcart, Andrea L.; Gupta, Sneha, V; Hwang, Carey; Gane, Edward | Univ Hong Kong, Sch Clin Med, Dept Med, Hong Kong, Peoples R China; Univ Hong Kong, Dept Microbiol, Hong Kong, Special Adm Reg, Peoples R China; Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea; Pusan Natl Univ, Yangsan Hosp, Liver Ctr, Yangsan, South Korea; Pusan Natl Univ, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Yangsan, South Korea; Middlemore Hosp, Dept Gastroenterol & Hepatol, Auckland, New Zealand; Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; Chulalongkorn Univ, Fac Med, Ctr Excellence Hepatitis & Liver Canc, Bangkok, Thailand; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Kyungpook Natl Univ Ho, Daegu, South Korea; Vir Biotechnol, San Francisco, CA USA; Univ Auckland, Dept Med & Hlth Sci, Auckland, New Zealand | Heo, Jeong/MHQ-1390-2025; Yuen, Richard Man Fung/C-4466-2009; Lim, Young-Suk/AFQ-5165-2022; Gane, Edward/AGN-7071-2022 | 7102031955; 57226548822; 14820137300; 56254681000; 8422238800; 7003646635; 7004074582; 55580316700; 57190307624; 59388600900; 58366043800; 55552589600; 57217374244; 55655986100; 7003720102 | mfyuen@hkucc.hku.hk; | LANCET GASTROENTEROLOGY & HEPATOLOGY | LANCET GASTROENTEROL | 2468-1253 | 9 | 12 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2024 | 38.6 | 1.0 | 7.19 | 2025-05-07 | 20 | 20 | STEM-CELL TRANSPLANTATION; FUNCTIONAL CURE; REACTIVATION; CHEMOTHERAPY; THERAPY; SAFETY | Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult; alanine aminotransferase; aspartate aminotransferase; chemicals and drugs; elebsiran; hepatitis B surface antigen; nucleotide reverse transcriptase inhibitor; peginterferon alpha2a; RNA directed DNA polymerase inhibitor; unclassified drug; alpha interferon; antivirus agent; hepatitis B surface antigen; macrogol derivative; peginterferon alpha2a; recombinant protein; virus DNA; adult; aged; antiretroviral therapy; Article; blood cell count; chronic hepatitis B; controlled study; drug safety; drug withdrawal; enzyme linked immunospot assay; female; human; immune response; limit of detection; limit of quantitation; liver function test; major clinical study; male; multicenter study; phase 1 clinical trial; phase 2 clinical trial; adolescent; blood; chronic hepatitis B; clinical trial; combination drug therapy; drug effect; drug therapy; genetics; Hepatitis B virus; immunology; middle aged; treatment outcome; young adult | English | 2024 | 2024-12 | 10.1016/s2468-1253(24)00237-1 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | (-)-Epicatechin reveals amoebicidal activity against Acanthamoeba castellanii by activating the programmed cell death pathway | Background: Acanthamoeba is an opportunistic pathogen that can cause human infections such as granulomatous amebic encephalitis and acanthamoeba keratitis. However, no specific drug to treat the diseases has been developed. Therefore, the discovery or development of novel drugs for treating Acanthamoeba infections is urgently needed. The anti-protozoan activity of (-)-epicatechin (EC) has been reported, suggesting it is an attractive anti-protozoal drug candidate. In this study, the amoebicidal activity of EC against A. castellanii was assessed and its mechanism of action was unveiled. Methods: The amoebicidal activity of EC against A. castellanii trophozoites and the cytotoxicity of EC in HCE-2 and C6 cells were determined with cell viability assay. The underlying amoebicidal mechanism of EC against A. castellanii was analyzed by the apoptosis/necrosis assay, TUNEL assay, mitochondrial dysfunction assay, caspase-3 assay, and quantitative reverse transcription polymerase chain reaction. The cysticidal activity of EC was also investigated. Results: EC revealed amoebicidal activity against A. castellanii trophozoites with an IC50 of 37.01 +/- 3.96 mu M, but was not cytotoxic to HCE-2 or C6 cells. EC induced apoptotic events such as increases in DNA fragmentation and intracellular reactive oxygen species production in A. castellanii. EC also caused mitochondrial dysfunction in the amoebae, as evidenced by the loss of mitochondrial membrane potential and reductions in ATP production. Caspase-3 activity, autophagosome formation, and the expression levels of autophagy-related genes were also increased in EC-treated amoebae. EC led to the partial death of cysts and the inhibition of excystation. Conclusion: EC revealed promising amoebicidal activity against A. castellanii trophozoites via programmed cell death events. EC could be a candidate drug or supplemental compound for treating Acanthamoeba infections. | Le, Huongng Giang; Kang, Jung-Mi; Vo, Tuan Cuong; Yoo, Won Gi; Hong, Yeonchul; Na, Byoung-Kuk | Gyeongsang Natl Univ, Coll Med, Dept Parasitol & Trop Med, Jinju 52727, South Korea; Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Jinju 52727, South Korea; Gyeongsang Natl Univ, Dept Convergence Med Sci, Jinju 52727, South Korea; Kyungpook Natl Univ, Sch Med, Dept Parasitol & Trop Med, Daegu 41944, South Korea | ; Na, b/KPY-6354-2024; Yoo, Won/O-8386-2018 | 57200567418; 7404517088; 57216850499; 35811429600; 7403392847; 7005291099 | bkna@gnu.ac.kr; | PHYTOMEDICINE | PHYTOMEDICINE | 0944-7113 | 1618-095X | 125 | SCIE | CHEMISTRY, MEDICINAL;INTEGRATIVE & COMPLEMENTARY MEDICINE;PHARMACOLOGY & PHARMACY;PLANT SCIENCES | 2024 | 8.3 | 1.1 | 1.16 | 2025-05-07 | 2 | 2 | Acanthamoeba; (-)-Epicatechin; Amoebicidal activity; Cysticidal activity; Programmed cell death | AUTOPHAGY; KERATITIS | (‒)-Epicatechin; Acanthamoeba; Amoebicidal activity; Cysticidal activity; Programmed cell death | adenosine triphosphate; caspase 3; epicatechin; reactive oxygen metabolite; adenosine triphosphate; caspase 3; epicatechin; reactive oxygen metabolite; Acanthamoeba castellanii; amoebicidal activity; apoptosis; apoptosis assay; Article; autophagic cell death; autophagy (cellular); C6 cell line (glioma); cell viability assay; controlled study; disorders of mitochondrial functions; DNA fragmentation; drug cytotoxicity; drug mechanism; enzyme activity; gene expression level; HCE cell line (colon epithelium); human; human cell; IC50; intracellular space; mitochondrial membrane potential; necrosis assay; nonhuman; real time reverse transcription polymerase chain reaction; trophozoite; TUNEL assay; Acanthamoeba; Acanthamoeba infection; Acanthamoeba keratitis; antiprotozoal activity; article; autophagosome; cytotoxicity; granulomatous amebic encephalitis; signal transduction | English | 2024 | 2024-03 | 10.1016/j.phymed.2024.155389 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | Meeting Abstract | A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) | Powles, T. B.; van der Heijden, M. S.; Galsky, M. D.; Al-Ahmadie, H.; Meeks, J. J.; Nishiyama, H.; Vu, T. Q.; Antonuzzo, L.; Wiechno, P.; Atduev, V.; Kann, A. G.; Kim, T-H.; Rodriguez, C. Suarez; Chang, C-H.; Roghmann, F.; Ozguroglu, M.; Armstrong, J.; Ho, S.; Hois, S.; Catto, J. | Queen Mary Univ London, Barts Canc Inst, Genitourinary Oncol, London, England; Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA; Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA; Northwestern Univ, Feinberg Sch Med, Dept Urol Biochem & Mol Genet, Chicago, IL USA; Univ Tsukuba, Dept Urol, Tsukuba, Ibaraki, Japan; Vietnam Natl Canc Hosp, Dept Internal Med 3, Hanoi, Vietnam; Univ Careggi, Azienda Osped, SODc Oncol Med, Florence, Italy; Maria Sklodowska Curie Natl Res Inst Oncol, Dept Urooncol, Warsaw, Poland; Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia; Hosp Alemao Oswaldo Cruz, Oncol Clin, Sao Paulo, Brazil; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Hosp Univ Vall Hebron, Vall Hebron Inst Oncol VHIO, Med Oncol, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain; China Med Univ & Hosp, Dept Urol, Taichung, Taiwan; China Med Univ & Hosp, Sch Med, Taichung, Taiwan; Ruhr Univ Bochum, Marien Hosp, Univ Hosp, Dept Urol, Herne, Germany; Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Internal Med, Istanbul, Turkey; AstraZeneca, Stat, Cambridge, England; AstraZeneca, Oncol, Gaithersburg, MD USA; Univ Sheffield, Sch Med & Populat Hlth, Div Clin Med, Sheffield, S Yorkshire, England; Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England | ANNALS OF ONCOLOGY | ANN ONCOL | 0923-7534 | 1569-8041 | 35 | SCIE | ONCOLOGY | 2024 | 65.4 | 1.1 | 1 | English | 2024 | 2024-09 | 10.1016/j.annonc.2024.08.2327 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Association study between genetic variants in regulatory gene for RNA modification and prognosis in non-small cell lung cancer | Lee, E.; Lee, S.; Choi, J. E.; Park, J. | Kyungpook Natl Univ, Chilgok Hosp, Thorac Surg, Daegu, South Korea; KNU Kyungpook Natl Univ, Dept Biochem & Cell Biol, Daegu, South Korea; KNUH Kyungpook Natl Univ, Dept Biochem & Cell Biol, Sch Med, Daegu, South Korea; KNU Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | ANNALS OF ONCOLOGY | ANN ONCOL | 0923-7534 | 1569-8041 | 35 | SCIE | ONCOLOGY | 2024 | 65.4 | 1.1 | 0 | English | 2024 | 2024-09 | 10.1016/j.annonc.2024.08.017 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Cbfβ prevents articular cartilage degeneration | Che, Xiangguo; Jin, Xian; Lee, Dong-Kyo; Kim, Hee-June; Kyung, Hee-Soo; Kim, Hyun-Ju; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.; Choi, Je-Yong | Kyungpook Natl Univ, Cell & Matrix Res Inst, Sch Med, Dept Biochem & Cell Biol, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Orthoped Surg, Daegu, South Korea; Univ Vermont, Dept Biochem, Coll Med, Burlington, VT USA; Univ Vermont, Ctr Canc, Coll Med, Burlington, VT USA | Choi, Je-Yong/AAR-7334-2021 | OSTEOARTHRITIS AND CARTILAGE | OSTEOARTHR CARTILAGE | 1063-4584 | 1522-9653 | 32 | 6 | SCIE | ORTHOPEDICS;RHEUMATOLOGY | 2024 | 9 | 1.1 | 0 | English | 2024 | 2024-06 | 10.1016/j.joca.2024.03.038 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||
| ○ | Meeting Abstract | CXCR4 IN ARTICULAR CHONDROCYTE MAY HAVE A PROTECTIVE EFFECT ON ADVANCED KNEE OSTEOARTHRITIS | Kim, Gunwoo; Cho, Hyun-Jung; Park, Hye-Ri; Lee, Eun-Ju; Jang, Jiae; Wee, Gabbine; Sung, Younghun; Park, Junyong; Lee, Sung Won; Che, Xiangguo; Choi, Je-Yong; Nam, Eon Jeong | Daegu Fatima Hosp, Rheumatol, Daegu, South Korea; Fatima Res Inst, Lab Arthrit & Bone Biol, Daegu, South Korea; Daegu Gyeongbuk Med Innovat Fdn, Preclin Res Ctr, Daegu, South Korea; Dong A Univ Hosp, Rheumatol, Busan, South Korea; Kyungpook Natl Univ, Sch Med, Biochem & Cell Biol, Daegu, South Korea; Kyungpook Natl Univ, Rheumatol, Chilgok Hosp, Daegu, South Korea | Choi, Je-Yong/AAR-7334-2021 | OSTEOARTHRITIS AND CARTILAGE | OSTEOARTHR CARTILAGE | 1063-4584 | 1522-9653 | 32 | SCIE | ORTHOPEDICS;RHEUMATOLOGY | 2024 | 9 | 1.1 | 1 | English | 2024 | 2024-04 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04 | Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Vidal Losada, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Prat, A.; Suto, F.; Kuwahara, Y.; Boran, A. D.; Kobayashi, M.; Kumar, V.; Aguilar, C. Orbegoso; Modi, S. | Univ Hawaii, Dept Breast Oncol, Ctr Canc, Honolulu, HI USA; Tokai Univ, Sch Med, Dept Breast Oncol, Hiratsuka, Kanagawa, Japan; Kanagawa Canc Ctr, Dept Breast & Endocrine Surg & Oncol, Yokohama, Kanagawa, Japan; Inst Canc Montpellier, Dept Med Oncol, Montpellier, France; Univ Edinburgh, Edinburgh Univ Canc Ctr, Western Gen Hosp, Dept Inst Genet & Canc, Edinburgh, Midlothian, Scotland; Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan; Yonsei Univ, Coll Med, Severance Hosp, Dept Med Oncol, Seoul, South Korea; NHO Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka, Japan; Hosp Clin Barcelona, Dept Med, Barcelona, Spain; Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea; Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea; Kyungpook Natl Univ, Sch Med, Chilgok Hosp, Dept Oncol, Daegu, South Korea; August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapies Grp, Barcelona, Spain; Daiichi Sankyo Inc, Dept Translat Sci, Basking Ridge, NJ USA; Daiichi Sankyo Co Ltd, Dept Translat Res Labs, Tokyo, Japan; Daiichi Sankyo Inc, Dept Precis Med, Basking Ridge, NJ USA; Daiichi Sankyo Inc, Dept Global Oncol R&D, Rueil Malmaison, France; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA | Losada, Maria/AAJ-8633-2021; Cameron, David/C-7781-2013 | ANNALS OF ONCOLOGY | ANN ONCOL | 0923-7534 | 1569-8041 | 35 | SCIE | ONCOLOGY | 2024 | 65.4 | 1.1 | 2 | English | 2024 | 2024-09 | 10.1016/j.annonc.2024.08.379 | 바로가기 | 바로가기 | 바로가기 | ||||||||||||||
| ○ | Meeting Abstract | Long-term clinical outcomes of acute myocardial infarction based on a center's experience with IVUS in the contemporary drug-eluting stent era | Kwon, Y.; Kim, N.; Kim, D. H.; Park, J. S.; Park, Y. J.; Park, B. E.; Oh, S.; Kim, H. N.; Jang, S. Y.; Bae, M. H.; Lee, J. H.; Yang, D. H.; Park, H. S.; Cho, Y. | Kyungpook Natl Univ Hosp, Daegu, South Korea; Daejeon Eulji Med Ctr, Daejeon, South Korea; Jeonju Presbyterian Med Ctr, Jeonju, South Korea | Lee, Jiwon/CAJ-1171-2022 | aquinaskwon@gmail.com; | EUROPEAN HEART JOURNAL | EUR HEART J | 0195-668X | 1522-9645 | 45 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2024 | 35.6 | 1.1 | 0 | English | 2024 | 2024-10-28 | 10.1093/eurheartj/ehae666.2338 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||
| ○ | ○ | Article | Membrane reciprocation and quorum quenching: An innovative combination for fouling control and energy saving in membrane bioreactors | Membrane bioreactors (MBRs) play a crucial role in wastewater treatment, but they face considerable challenges due to fouling. To tackle this issue, innovative strategies are needed. This study investigated the effectiveness of membrane reciprocation and quorum quenching (QQ) to control fouling in MBRs. The study compared MBRs using membrane reciprocation (30 rpm) and QQ (injecting media containing 100 or 200 mg/L BH4) with conventional MBRs employing different air-scouring intensities. The results demonstrated that combining membrane reciprocation (30 rpm) with QQ (200 mg/L BH4) significantly extended the service time of MBRs, making it approximately six times longer than conventional methods. Moreover, this approach reduced physically reversible resistance. The reduction in signal molecules related to biofouling due to QQ showcased its critical role in controlling biofouling, even under high shear caused by membrane reciprocation. However, the impact of QQ on microbial community structure appeared relatively insignificant when compared to factors such as operation time, aeration intensity, and membrane reciprocation. By combining membrane reciprocation and QQ, the study achieved a remarkable 81 % energy saving compared to extensive aeration (103 s-1 in velocity gradient), in addition to the extended service time. Importantly, this combined antifouling approach did not negatively affect microbial characteristics and wastewater treatment, emphasizing its effectiveness in MBRs. Overall, the findings of this study offer valuable insights for developing synergistic fouling control strategies in MBRs, significantly improving the energy efficiency of the wastewater treatment process. | Kim, Jinwoo; Bae, Eunjin; Park, Hyeona; Park, Hyung-June; Shah, Syed Salman Ali; Lee, Kibaek; Lee, Jaewoo; Oh, Hyun-Suk; Park, Pyung-Kyu; Shin, Yong Cheol; Moon, Heewan; Naddeo, Vincenzo; Choo, Kwang-Ho | Kyungpook Natl Univ, Sch Architectural Civil Environm & Energy Engn, 80 Daehak Ro,Buk Gu, Daegu 41566, South Korea; Water Qual Res Inst, Daegu Metropolitan City Waterworks Headquarters, 176 Dangsan Ro,Dalseo Gu, Daegu 42650, South Korea; Kyungpook Natl Univ, Adv Inst Water Ind, 80 Daehak Ro,Buk Gu, Daegu 41566, South Korea; Beijing Normal Univ Zhuhai, Adv Inst Nat Sci, Ctr Water Res, Zhuhai 519087, Guangdong, Peoples R China; Chonnam Natl Univ, Dept Biotechnol & Bioengn, Gwangju 61186, South Korea; Jeonbuk Natl Univ, Dept Polymer Nano Sci & Technol, 567 Baekje Daero,Deokjin Gu, Jeonju 54896, South Korea; Seoul Natl Univ Sci & Technol, Dept Environm Engn, Seoul 01811, South Korea; Yonsei Univ, Dept Environm & Energy Engn, Wonju 26439, South Korea; HifilM, 24 Deokseongsandan 2 Ro,Idong Eup, Yongin 17130, Gyeonggi Do, South Korea; Univ Salerno, Dept Civil Engn, Sanit Environm Engn Div, via Giovanni Paolo 2, I-84084 Fisciano, SA, Italy; Kyungpook Natl Univ, Dept Environm Engn, 80 Daehak Ro,Buk Gu, Daegu 41566, South Korea | ; Oh, Hyun-Suk/G-4843-2017; Shah, Syed Salman Ali/JCE-1663-2023; Choo, Kwang-Ho/A-3456-2016; Lee, Jaewoo/L-2118-2019; Naddeo, Vincenzo/C-4057-2008; Shin, Yong Cheol/C-9872-2015 | 57901150400; 58788844000; 57213039681; 57213039678; 57215722996; 55845961700; 55503061900; 8212183100; 7202425104; 57679610300; 58788844100; 57225215311; 7102083272 | chookh@knu.ac.kr; | WATER RESEARCH | WATER RES | 0043-1354 | 1879-2448 | 250 | SCIE | ENVIRONMENTAL SCIENCES;WATER RESOURCES;ENGINEERING, ENVIRONMENTAL | 2024 | 12.4 | 1.1 | 4.95 | 2025-05-07 | 15 | 16 | Biofouling; Energy saving; Membrane bioreactor; Membrane reciprocation; Quorum quenching | BIOFOULING CONTROL; EFFICIENT MEMBRANE; MBR; AERATION; BACTERIA; PERFORMANCE; SLUDGE | Biofouling; Energy saving; Membrane bioreactor; Membrane reciprocation; Quorum quenching | Biofouling; Bioreactors; Membranes, Artificial; Quorum Sensing; Water Purification; Bioconversion; Biofouling; Energy efficiency; Membranes; Quenching; Surface treatment; Wastewater treatment; nitrogen; phosphorus; Air scouring; Conventional membrane bioreactors; Energy savings; Energy-savings; Fouling control; Innovative strategies; Membrane bioreactor; Membrane reciprocation; Quorum quenching; Service time; antifouling; biofouling; bioreactor; energy conservation; energy efficiency; innovation; membrane; microbial community; reduction; aeration; analytic method; Article; biofouling; chemical oxygen demand; comparative study; cost; cross linking; energy conservation; filtration; fouling control; gene sequence; high throughput sequencing; membrane; membrane resistance; microbial community; nonhuman; quorum quenching; sludge; solids retention time; suspended particulate matter; total organic carbon; waste water management; artificial membrane; biofouling; prevention and control; procedures; quorum sensing; water management; Bioreactors | English | 2024 | 2024-02-15 | 10.1016/j.watres.2023.121035 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Editorial Material | Obesity paradox can be a fact: unveiling the hidden role of adipose tissue | Lee, Duk-Hee | Kyungpook Natl Univ, Dept Prevent Med, Sch Med, 680 Gukchaebosang Ro, Daegu 41944, South Korea | 57211851121 | lee_dh@knu.ac.kr; | EUROPEAN HEART JOURNAL | EUR HEART J | 0195-668X | 1522-9645 | 45 | 24 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2024 | 35.6 | 1.1 | 2.09 | 2025-05-07 | 1 | 1 | PERSISTENT ORGANIC POLLUTANTS | Adipose Tissue; Cardiovascular Diseases; Humans; Obesity; Obesity Paradox; adipose tissue; body mass; cardiovascular risk factor; heart failure with reduced ejection fraction; human; Note; obesity paradox; randomized controlled trial (topic); cardiovascular disease; complication; etiology; mortality; obesity; obesity paradox | English | 2024 | 2024-05-17 | 10.1093/eurheartj/ehae236 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||||
| ○ | Meeting Abstract | Real-world treatment (Tx) patterns in patients (pts) with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HER2+aGC/GEJC) in East Asia (HER2+GASTA) | Oh, D-Y.; Yeo, W.; Chen, J-S.; Ba, Y.; Chan, W. W. L.; Chen, M-J.; Chen, Y. H.; Gu, K.; Hung, Y-P.; Kim, J. G.; Lee, J.; Liang, X.; Luo, S.; Rha, S. Y.; Yuan, Y.; Kim, T.; Yanagida, M.; Sato, R.; Xu, R-H. | Seoul Natl Univ Hosp, Internal Med Dept, Seoul, South Korea; Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China; Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Hematol Oncol Dept, Taoyuan, Taiwan; TMUCIH Tianjin Med Univ Canc Inst & Hosp, Dept GI Med Oncol, Tianjin, Peoples R China; Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China; Mackay Mem Hosp Tamsui Branch, Div Colorectal Surg, New Taipei, Taiwan; Kaohsiung Chang Gung Mem Hosp, Chang Gung Med Fdn, Oncol Dept, Kaohsiung, Taiwan; Anhui Med Univ, Dept Oncol, Affiliated Hosp 1, Hefei, Peoples R China; Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan; Kyungpook Natl Univ, Oncol Dept, Med Ctr, Biobank,Chilgok Hosp, Daegu, South Korea; Sungkyunkwan Univ, Basic Sci & Translat Res, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea; HuBei Canc Hosp, Dept Oncol, Wuhan, Peoples R China; Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China; Henan Canc Hosp, Zhengzhou, Peoples R China; Yonsei Univ, Med Oncol Dept, Seoul, South Korea; Zhejiang Univ, Med Oncol, Affiliated Hosp 2, Sch Med East Gate 1, Hangzhou, Peoples R China; Lin Korea Co Ltd, STAT, Seoul, South Korea; Daiichi Sankyo Co Ltd, ASCA Business Div, ASCA Oncol Product Dept, Chuo Ku, Chuo City, Japan; Daiichi Sankyo Co Ltd, Med Affairs, Chuo Ku, Chuo City, Japan; Sun Yat Sen Univ, Med Oncol Dept, Canc Ctr, Guangzhou, Peoples R China | ANNALS OF ONCOLOGY | ANN ONCOL | 0923-7534 | 1569-8041 | 35 | SCIE | ONCOLOGY | 2024 | 65.4 | 1.1 | 0 | English | 2024 | 2024-12 | 10.1016/j.annonc.2024.10.206 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | THE INTERPLAY BETWEEN ENDOPLASMIC RETICULUM STRESS AND OXIDATIVE STRESS IN CHONDROCYTE CATABOLISM | Kim, Yu Jung; Han, Jin; Han, Seungwoo | Kyungpook Natl Univ Hosp, Internal Med, Daegu, South Korea | Kim, Tae-Hee/AAN-9079-2021 | OSTEOARTHRITIS AND CARTILAGE | OSTEOARTHR CARTILAGE | 1063-4584 | 1522-9653 | 32 | SCIE | ORTHOPEDICS;RHEUMATOLOGY | 2024 | 9 | 1.1 | 0 | English | 2024 | 2024-04 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | Tumor-immune spatial interactions on NSCLC H&E slide images predicts immunotherapy response: Preliminary external validation | Chung, L. I-Y.; Li, H.; Kim, L.; Lee, S.; Maghsoudi, O. Haji; Hiremath, A.; Lee, J.; Kim, P. Haseok; Lee, S.; Yadav, M.; Chuchuca, M. J. A.; Um, T.; Kim, Y.; Hong, I.; Kang, G.; Cho, A.; Cooper, L.; Madabhushi, A.; Braman, N.; Chae, Y. K. | Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Picture Hlth, Cleveland, OH USA; Ascens St Francis, Evanston, IL USA; Kyungpook Natl Univ, Daegu, South Korea; Univ Texas Austin, UT Hlth Austin, Austin, TX 78712 USA; Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA; Northwestern Univ, Chicago, IL 60611 USA; Emory Univ, Biomed Engn, Atlanta, GA 30322 USA | Chung, Liam Il-Young/IQU-0821-2023 | ANNALS OF ONCOLOGY | ANN ONCOL | 0923-7534 | 1569-8041 | 35 | SCIE | ONCOLOGY | 2024 | 65.4 | 1.1 | 0 | English | 2024 | 2024-09 | 10.1016/j.annonc.2024.08.2172 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: